...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
【24h】

Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.

机译：与西布曲明相比，度洛西汀的抗肥胖活性及其抗抑郁活性的评估：一项针对肥胖大鼠的实验研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

5-HT and noradrenaline are important neurotransmitters that control increase in body mass and are involved in the pathophysiology of obesity and depression. Sibutramine, an established anti-obesity agent, and duloxetine, an anti-depressant agent, are serotonin noradrenaline reuptake inhibitors (SNRIs). The objective of the present study was to compare the anti-obesity effect of duloxetine with sibutramine along with its effect on blood pressure and depression in obese rats. The secondary objective of the study was to determine if a relationship exists between obesity and depression. Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats. After 5 weeks of feeding HFD, animals were overweight (17.57%) with high food intake (57.15%) in comparison with normal animals. These obese animals were treated with duloxetine (30 mg x kg(-1), p.o.) and sibutramine (5 mg x kg(-1), p.o.) for 4 weeks. Control animals were treated with duloxetine alone (30 mg x kg(-1), p.o.). Our results depict that duloxetine was as effective as sibutramine in reducing food intake, body mass, and relative adiposity, and increasing rectal temperature with an added advantage of decreasing blood pressure, which sibutramine failed to do. Besides reduction in body mass, unlike sibutramine, duloxetine improved depressive state as evaluated by despair swimming test, tail suspension test, and open field test, speculating its use as an anti-obesity agent in obese-depressive animals. Since obese control animals reflected decreased locomotor activity, a positive relationship can be speculated to exist between obesity and depression. Further studies on various antidepressant models are required to confirm this relationship.
机译：5-HT和去甲肾上腺素是重要的神经递质，可控制体重增加，并参与肥胖和抑郁症的病理生理。西布曲明（一种公认的抗肥胖药）和度洛西汀（一种抗抑郁药）是5-羟色胺去甲肾上腺素再摄取抑制剂（SNRIs）。本研究的目的是比较度洛西汀和西布曲明的抗肥胖作用以及它对肥胖大鼠血压和抑郁的影响。该研究的次要目的是确定肥胖与抑郁之间是否存在联系。在健康的雄性Sprague-Dawley大鼠中，高脂饮食（HFD）诱发了肥胖。喂食HFD 5周后，与正常动物相比，动物超重（17.57％），食物摄入量较高（57.15％）。这些肥胖的动物接受度洛西汀（30 mg x kg（-1），p.o.）和西布曲明（5 mg x kg（-1），p.o.）治疗4周。对照动物仅用度洛西汀治疗（30 mg x kg（-1），p.o。）。我们的研究结果表明，度洛西汀在减少食物摄入，体重和相对肥胖以及增加直肠温度方面具有与西布曲明同等的效果，同时具有降低血压的其他优势，而西布曲明无法做到。除了减少体重外，与西布曲明不同，度洛西汀还可以通过绝望游泳测试，尾部悬吊测试和野外测试来改善抑郁状态，推测其在肥胖抑郁动物中可用作抗肥胖药。由于肥胖对照动物反映出运动能力下降，因此可以推测肥胖与抑郁之间存在正相关关系。需要进一步研究各种抗抑郁药模型以确认这种关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号